



RECEIVED

Patent Docket # 1740
SEP 19 2001
TECH CENTER 1600/2900
9-28-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Nicholas Van Bruggen et al. Serial No.: 09/218,481 Filed: December 22, 1998 For: VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTOAGONISTS AND USES THEREOF	Group Art Unit: 1642 Examiner: S. Ungar CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on September 7, 2001 Eileen Ly
---	---

AMENDMENT UNDER 37 C.F.R. §1.116

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This communication is responsive to the Office Action mailed March 9, 2001. Applicants submit concurrently herewith a Request for Continued Examination (RCE) and a request for a three-month extension along with the required fee.

Please note that the Power of Attorney for the instant application has been changed pursuant to a Revocation and Power of Attorney submitted September 21, 2000. Accordingly, please send all future communications to the undersigned attorney directly.

Please amend the application as follows and consider the remarks set forth thereafter.

I. AMENDMENTS

In the Claims:

Please amend claims 1 and 8 as follows:

1. (Amended) A method of reducing cerebral edema in a mammal, comprising administering to said mammal a hVEGF antagonist in an amount effective to reduce the volume of cerebral edema in the brain of the mammal, wherein said antagonist comprises an anti-hVEGF antibody.

D
Sub
E